Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lexicon Pharmaceuticals (LXRX)
:LXRX
RESEARCH TOOLSreports
LXRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.62 - $2.83
Previous CloseN/A
Volume2.02M
Average Volume (3M)4.96M
Market Cap
$275.75M
Enterprise Value$415.05M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.40
Next Earnings
Mar 12, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding361,492,300
10 Day Avg. Volume3,486,289
30 Day Avg. Volume4,955,155
Standard Deviation0.31
R-Squared0.03
Alpha0.00269
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)51.02
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit370.91
Enterprise Value/Ebitda-2.08
Forecast
1Y Price Target
$5.07Price Target Upside594.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Lexicon Pharmaceuticals News
PremiumCompany Announcements
Lexicon Pharmaceuticals Appoints New CFO Scott M. Coiante
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe upcoming potentially validating Ph.2 data catalyst for LX9211 could spur partnership discussions and represent significant market opportunities.
Market PotentialLX9211 is well-positioned to address the need for improved DPNP therapies, as current treatments focus on symptoms rather than the root cause.
Research And DevelopmentThe meticulously designed PROGRESS Phase 2b study should de-risk LX9211’s later-stage clinical development.
Bears Say
CompetitionDPNP represents a huge opportunity for disruptive innovations, with approximately 9 million patients diagnosed in the US, and a 50% increase estimated over the next decade.
Investor AwarenessLexicon's LX9211 program for diabetic peripheral neuropathic pain has a novel oral, 1x-daily non-opioid profile that is still overlooked by investors at current stock levels.
Regulatory And Development RisksPatient randomization underway in the registrational SONATA-HCM Phase 3 trial, which is the first clinical trial evaluating the effects of SGLT inhibition on CV outcomes in patients with HCM.
---
Ownership Overview
51.08% Insiders
11.75% Mutual Funds
0.25% Other Institutional Investors
32.30% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LXRX FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was $0.62 and its highest was $2.83 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Lexicon Pharmaceuticals’s market cap is $275.75M.
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s upcoming earnings report date is Mar 12, 2025 which is in 19 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.163 by -$0.017.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate is -0.13.
How many shares outstanding does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals has 361,492,300 shares outstanding.
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.163. Following the earnings report the stock price went down -8.403%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Currently, no hedge funds are holding shares in LXRX
---
Lexicon Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.07 (594.52% Upside)
$5.07 (594.52% Upside)
Blogger Sentiment
Bullish
LXRX Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.60%
12-Months-Change
Fundamentals
Return on Equity
-135.14%
Trailing 12-Months
Asset Growth
16.15%
Trailing 12-Months
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
---
LXRX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant progress in clinical development and strategic partnerships, particularly the resubmission of the NDA for ZYNQUISTA and the Viatris agreement. However, challenges were noted with modest sales growth for INPEFA and increased financial losses. The FDA Advisory Committee's negative vote on ZYNQUISTA's benefits versus risks is a notable setback.Read More>---
LXRX Stock 12 Month Forecast
Average Price Target
$5.07
▲(594.52% Upside)
Technical Analysis
Best Analysts Covering LXRX
1 Year
1 Year Success Rate
5/18 ratings generated profit
1 Year Average Return
-16.88%
reiterated a buy rating 3 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 27.78% of your transactions generating a profit, with an average return of -16.88% per trade.
---